platycodin D
| Name | Platycodin D | ||
| PubChem CID | 162859 | ||
| Molecular Weight | 1225.3g/mol | ||
| Synonyms |
platycodin D |
||
| Formula | C₅₇H₉₂O₂₈ | ||
| SMILES | CC1C(C(C(C(O1)OC2C(C(COC2OC(=O)C34CCC(CC3C5=CCC6C(C5(CC4O)C)(CCC7C6(CC(C(C7(CO)CO)OC8C(C(C(C(O8)CO)O)O)O)O)C)C)(C)C)O)O)O)O)OC9C(C(C(CO9)O)OC1C(C(CO1)(CO)O)O)O | ||
| InChI | 1S/C57H92O28/c1-23-40(81-45-39(72)41(28(64)18-76-45)82-49-43(73)56(75,21-61)22-78-49)36(69)38(71)46(79-23)83-42-33(66)27(63)17-77-48(42)85-50(74)57-12-11-51(2,3)13-25(57)24-7-8-30-52(4)14-26(62)44(84-47-37(70)35(68)34(67)29(16-58)80-47)55(19-59,20-60)31(52)9-10-53(30,5)54(24,6)15-32(57)65/h7,23,25-49,58-73,75H,8-22H2,1-6H3/t23-,25-,26-,27-,28+,29+,30+,31+,32+,33-,34+,35-,36-,37+,38+,39+,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,52+,53+,54+,56+,57+/m0/s1 | ||
| InChIKey | CYBWUNOAQPMRBA-NDTOZIJESA-N | ||
| CAS Number | 58479-68-8 | ||
| ChEMBL ID | CHEMBL1641859 | ||
| ChEBI ID | CHEBI:70436 | ||
| KEGG ID | C17410 | ||
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | JieGeng | ||
| Use Part | Root | ||
| Habitat | China | ||
| Flavor | Bitter, Pungent | ||
| Meridian Tropism | Lung | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Asterales
-->Family: Campanulaceae
-->Genus: Platycodon
-->Species: Platycodon grandiflorus
|
||
| Pair Name | Platycodin D, Cetuximab | |||
| Partner Name | Cetuximab | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Inhibition-->Cell metastasis | |||
| Gene Regulation | Down-regulation | Expression | CCND1 | hsa595 |
| Down-regulation | Expression | CTNNB1 | hsa1499 | |
| Down-regulation | Expression | MMP7 | hsa4316 | |
| Down-regulation | Expression | MYC | hsa4609 | |
| In Vitro Model | HT-29 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0320 |
| Caco-2 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0025 | |
| In Vivo Model | HT29 and CaCo2 cells were trypsinized and injected into the tail vein of nu/nu nude mice with a concentration of 2×10⁵/0.2 ml to establish a model for metastatic lung tumors. | |||
| Result | Our findings provide a potential strategy to inhibit CRC metastasis during cetuximab therapy by addition of platycodin D. | |||
| Pair Name | Platycodin D, Venetoclax | |||
| Partner Name | Venetoclax | |||
| Disease Info | [ICD-11: 2A60.Z] | Acute myeloid leukemia | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Expression | BAK1 | hsa578 | |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | BCL-xL | hsa598 | |
| Up-regulation | Expression | BIM | hsa10018 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | CYCS | hsa54205 | |
| Down-regulation | Phosphorylation | GSK3B | hsa2932 | |
| Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| Up-regulation | Expression | MCL1 | hsa4170 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Phosphorylation | S6K1 | KEGG ID N.A. | |
| In Vitro Model | MV4-11 | Childhood acute monocytic leukemia | Homo sapiens (Human) | CVCL_0064 |
| THP-1 | Childhood acute monocytic leukemia | Homo sapiens (Human) | CVCL_0006 | |
| Result | Platycodin D may be a potent therapeutic candidate for the treatment of AML | |||
| Pair Name | Platycodin D, Oxaliplatin | |||
| Partner Name | Oxaliplatin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Inhibition-->Cell metastasis | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Expression | MKI67 | hsa4288 | |
| Up-regulation | Expression | PSMD9 | hsa5715 | |
| Down-regulation | Phosphorylation | WWTR1 | hsa25937 | |
| Down-regulation | Phosphorylation | YAP1 | hsa10413 | |
| In Vitro Model | LoVo | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0399 |
| Result | Our results showed that PD is suitable as a promising agent for overcoming oxaliplatin-resistant colorectal cancer. | |||
| Pair Name | Platycodin D, Sorafenib | |||
| Partner Name | Sorafenib | |||
| Disease Info | [ICD-11: 2C82] | Prostate cancer | Investigative | |
| Biological Phenomena | Inhibition-->Cell proliferation | |||
| Gene Regulation | Up-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Expression | BIM | hsa10018 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | CCND1 | hsa595 | |
| Down-regulation | Expression | CDK4 | hsa1019 | |
| Down-regulation | Expression | CDK6 | hsa1021 | |
| Up-regulation | Expression | FASLG | hsa356 | |
| Up-regulation | Expression | FOXO3 | hsa2309 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Up-regulation | Expression | TNFSF10 | hsa8743 | |
| In Vitro Model | PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 |
| DU145 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0105 | |
| In Vivo Model | PC3 cells (shRNA-FOXO3a cells and MOCK cells) were injected subcutaneously into the left inguinal area of nude mice (BALB/c, nu/nu, male, 6-8 weeks old) | |||
| Result | The combination of Platycodin D and sorafenib may exert potent anti-cancer effects specifically via FOXO3a | |||
| Pair Name | Platycodin D, Histone deacetylase inhibitor | |||
| Partner Name | Histone deacetylase inhibitor | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Down-regulation | Phosphorylation | CFL1 | hsa1072 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| In Vitro Model | HA22T/VGH | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_7046 |
| HDACi-R | HDACi-R cell line was established from HA22T cells as described previously | Homo sapiens (Human) | N.A. | |
| Result | Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation | |||
| No. | Title | Href |
|---|---|---|
| 1 | Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells. Clin Exp Metastasis. 2023 Aug;40(4):339-356. doi: 10.1007/s10585-023-10218-6. | Click |
| 2 | Platycodin D induces apoptotic cell death through PI3K/AKT and MAPK/ERK pathways and synergizes with venetoclax in acute myeloid leukemia. Eur J Pharmacol. 2023 Oct 5;956:175957. doi: 10.1016/j.ejphar.2023.175957. | Click |
| 3 | Platycodin D confers oxaliplatin Resistance in Colorectal Cancer by activating the LATS2/YAP1 axis of the hippo signaling pathway. J Cancer. 2023 Jan 22;14(3):393-402. doi: 10.7150/jca.77322. | Click |
| 4 | Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer. Front Oncol. 2021 May 7;11:648985. doi: 10.3389/fonc.2021.648985. | Click |
| 5 | Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation. Phytomedicine. 2021 Feb;82:153442. doi: 10.1016/j.phymed.2020.153442. | Click |
